合作類型：技術(shù) 業(yè)類別: 生物科學(xué)與健康 過期時(shí)間：2015年10月08日
德國(guó)企業(yè)提供在生命科學(xué)領(lǐng)域，與生物技術(shù)研究伙伴在新型基因載體技術(shù)上共同合作研發(fā)，目前該企業(yè)正在尋求許可證協(xié)議或合資企業(yè)協(xié)議。
英文原文: Technologies for new biopharmaceutical compounds and diagnostics (08 DE 1169 27FU)| Germany| OFFER|19.12.2012 A German SME offers biotechnology research partnerships for the life-science industry based upon a new gene carrier technology for the development of biopharmaceutical compounds or diagnostic targets. The method of targeted genetic conditioning (TGC) enables immediate use of information from the analysis of genes and proteins and thereby allows access to targeted genetic conditioning of animal cells themselves. The company is looking for a license or joint-venture agreement. Listeria monocytogenes is an intracellularly growing grampositive bacterium that is usually known as a pathogenic germ acquired through contaminated food. It has a number of interesting inherent properties that renders it an ideal carrier organism for proteins and DNA. The German company modified and mutated Listeria in order to allow the development of a dual-use technology platform that can be used for the targeted induction of antibodies against specific epitopes as well as for the targeted transfection of eucaryotic cells to generate high producing cell lines for pharmacological production. These mutant Listeria are highly efficient and specific and are either apathogen or have a reduced pathogenicity. With a special service programme containing the processing of tailor-made monoclonal antibodies for difficult immunisation processes with complex antigens structures, the German company successfully applied the proprietary expertise for projects in this niche. The novel dual-use platform technology is based on the inherent properties of the gram-positive bacteria Listeria spec. One use of the technology consists in the targeted induction of immune responses to distinct epitopes, thus allowing a specific vaccination against the epitopes or proteins of choice as well as the targeted induction and generation of monoclonal antibodies. The targeted induction of immune response is achieved by coupling the epitopes or the proteins covalently to the surface of the live bacteria, inactivating and injecting them. Within a few days an immune response to the epitope will develop that can be optimised and enhanced by boostering injections. After a few weeks the animals show a very high antibody titre against the epitope. This technique is especially useful for the generation of monoclonal antibodies against epitopes consisting of just a few amino acids, against chemical substances, for the distinction between post-transcriptionally modified epitopes and non- or differently modified epitopes. Furthermore, by coupling complete proteins highly efficient and specific antibodies against the proteins can be generated. The platform technology also offers a fundamentally new approach to transfecting eukaryotic cell lines. It is applicable for the rapid generation of high producing eukaryotic cell clones and thus for the efficient production of recombinant proteins in eukaryotic cells. The technology uses the inherent capacity of Listeria to grow within the cytoplasm of eukaryotic cells. DNA transfer to the eukaryotic target cells happens after death of the bacteria and the DNA then transfects the eukaryotic cells. Generally the integration of the transferred DNA occurs in transcriptionally highly active regions of the genome and thus allows for strong expression of the target genes. This technology is useful for the generation of cell lines for pharmacological productions and basic research. Also, recombinant proteins can be expressed on demand.
